T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors

Ähnliche Einträge

• Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
  von: Laksmi Wulandari, et al.
  Veröffentlicht: (2018-07-01)
• Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients
  von: Wulandari, Laksmi, et al.
  Veröffentlicht: (2020)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  von: Huang, Yen-Hsiang, et al.
  Veröffentlicht: (2018)
• Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
  von: Jiang, Zhansheng, et al.
  Veröffentlicht: (2018)
• Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
  von: Chai CS, et al.
  Veröffentlicht: (2020-07-01)